Evaluating the intersection between sexually transmitted infections, inflammation and reproductive success
评估性传播感染、炎症和生殖成功之间的交叉点
基本信息
- 批准号:10115581
- 负责人:
- 金额:$ 10.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-01 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse eventAgeAnti-Inflammatory AgentsAspirinBiological AssayBirthBirth RateBloodBlood PlateletsC-reactive proteinCellsChlamydiaChlamydia trachomatisChronicCicatrixClinicalConceptionsCouplesDataDecidual Cell ReactionsDefectDiagnosisDiagnosticDiseaseDoseEndometrialEpigenetic ProcessEpithelial CellsEventExposure toFamilyFertilityFrequenciesFundingFutureGoalsGrowthHigh PrevalenceIL6 geneIL8 geneImmuneImmune signalingImmunologic ReceptorsInfectionInfertilityInflammationInterleukin-15LaboratoriesLeadLegal patentLinkLive BirthMeasurementMeasuresMediatingMenstrual cycleMetadataMethodsMissionMorbidity - disease rateMycoplasmaMycoplasma genitaliumNatural ImmunityNatureNeisseria gonorrhoeaeOutcomePGF genePTGS2 genePathogenesisPathologyPathway interactionsPhenotypePlacebosPlacentationPlasmaPopulationPregnancyPregnancy HistoriesPregnancy lossPrevalencePreventionProstaglandinsPublic HealthRandomizedRecording of previous eventsReproductionReproductive HealthReproductive MedicineResearchResearch SupportRiskRouteSTI preventionSerologySeroprevalencesSerumServicesSexually Transmitted DiseasesSterilityStimulusSubfecunditySurveysTarget PopulationsThromboxane A2TimeTissuesTrainingTrichomonas vaginalisTubeUnited States National Institutes of HealthVariantVascular Endothelial Growth FactorsWomanWomen&aposs GroupWorkadverse event riskadverse outcomeangiogenesiscytokineearly pregnancy lossfetalhigh riskhigh risk populationhistone modificationhuman diseaseimprovedimproved outcomeinflammatory markerinnovationinsightinterestmemberobstetric carepathogenreproductivereproductive morbidityreproductive outcomereproductive successreproductive tractseropositivesubfertilitytime-to-pregnancytissue repairtrying to conceivetubal infertilityyoung adult
项目摘要
PROJECT SUMMARY ABSTRACT
Pregnancy loss occurs in ~20% of women with a clinically recognized pregnancy. Couples with histories of
pregnancy loss represent a large portion of those trying to conceive, but treatment is limited to widely
inaccessible fertility services. Data from the Effects of Aspirin in Gestation and Reproduction (EAGeR) Trial has
shown that preconception low-dose Aspirin therapy increases birth rates in women with histories of pregnancy
loss when preconception chronic low-grade inflammation, determined by C-reactive protein, is present. There is
a critical need to understand pathways that result in preconception chronic low-grade inflammation. This would
help to identify a broader group of women whom would benefit from aspirin therapy and inform the use of aspirin
in reproductive medicine. We hypothesize that prior exposure to common sexually transmitted infections (STIs)
can lead to long-term immune dysregulation and defective tissue repair. Among women with histories of
pregnancy loss, STI serology may indicate subsequent risk of adverse events or represent a group of women
who would benefit from preconception anti-inflammatory therapy. Prevalent and mostly asymptomatic STIs such
as Chlamydia trachomatis and Mycoplasma genitalium can ascend to the upper genital tract causing endometrial
inflammation, tissue damage and scarring. Unfortunately, most women acquire these STIs as young adults, but
do not know they were ever infected. The concept of “trained innate immunity” posits that innate immune cells
can develop a long-term proinflammatory phenotype following infectious stimuli induced through epigenetic
changes to immune and epithelial cells. Indeed, these STIs are linked to tubal infertility but associations with
other measures of impaired fecundity are limited. The specific aims of this proposal will: 1) determine if
seropositivity to Chlamydia trachomatis and Mycoplasma genitalium influences time-to-pregnancy, pregnancy
loss and birth rates in women with histories of pregnancy loss while adjusting for other STIs known to infect the
upper genital tract. 2) Determine if STI seropositive women have a unique blood immune and angiogenic profile
compared to seronegative women. 3) Determine if STI seropositive women previously randomized to Aspirin
therapy as part of the EAGeR trial (results described above) have improved birth outcomes. This study will
include 1078 women from the EAGeR trial. All women have histories of pregnancy loss but no history of infertility.
Access to preconception data from a study with extremely detailed reproductive outcomes is unique. Additionally,
our team includes a world-leader in STI diagnostics, which allows for robust serological measurements. We will
also leverage the expertise of our team members, currently funded to develop methods to address
generalizability, to transport our results to our target population of US women with histories of pregnancy loss
using the National Survey of Family Growth. Given the profound increase in STI prevalence in the U.S. and the
frequency of pregnancy loss, this study and our future work could impact a large number of women.
项目总结摘要
在临床确认怀孕的妇女中,约20%会发生妊娠丢失。有婚姻历史的夫妇
妊娠丢失占试图怀孕的人的很大一部分,但治疗仅限于广泛
难以获得的生育服务。阿司匹林对妊娠和生殖的影响(EARGE)试验的数据已经
有孕产史的妇女中,先入为主的小剂量阿司匹林治疗会增加出生率
当先入为主的慢性低度炎症(由C-反应蛋白确定)时的损失。的确有
迫切需要了解导致先入为主的慢性低度炎症的途径。这将会
帮助确定将从阿司匹林治疗中受益的更广泛的妇女群体,并告知阿司匹林的使用
在生殖医学方面。我们假设之前接触过常见性传播感染(STI)
会导致长期免疫失调和组织缺陷修复。有吸毒史的女性中
妊娠丢失、性传播感染血清学检测可能提示后续不良事件的风险或代表一组妇女
谁将从先入为主的抗炎治疗中受益。流行且大多无症状的性传播疾病,如
由于沙眼衣原体和生殖支原体可以上升到上生殖道,导致子宫内膜
炎症、组织损伤和疤痕形成。不幸的是,大多数女性在年轻时就感染了这些性传播疾病,但
不知道他们曾经被感染过。“训练有素的先天免疫”的概念假定先天免疫细胞
可在通过表观遗传诱导的感染刺激后形成长期的促炎表型
免疫细胞和上皮细胞的变化。事实上,这些性传播感染与输卵管性不孕症有关,但与
其他衡量生育能力受损的指标也是有限的。这项提案的具体目标将:1)确定
沙眼衣原体和生殖支原体血清阳性对妊娠时间的影响
有妊娠流失史的妇女的失败率和出生率,同时调整了其他已知的感染
上生殖道。2)确定STI血清阳性妇女是否具有独特的血液免疫和血管生成特征
与血清阴性的女性相比。3)确定之前随机使用阿司匹林的STI血清阳性妇女
作为急切试验的一部分的治疗(结果如上所述)改善了分娩结果。这项研究将
包括来自急切试验的1078名女性。所有女性都有流产史,但没有不孕史。
从一项具有极其详细的生育结果的研究中获得先孕数据是独一无二的。另外,
我们的团队包括一位STI诊断领域的世界领先者,这使得强大的血清学测量成为可能。我们会
还利用我们团队成员的专业知识,目前他们被资助开发方法来解决
概括性,将我们的结果传递给我们的目标人群--有妊娠流产史的美国女性
使用全国家庭成长调查。鉴于性传播感染在美国和美国的发病率大幅上升
妊娠丢失的频率,这项研究和我们未来的工作可能会影响大量女性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brandie DePaoli Taylor其他文献
Preconception emChlamydia trachomatis/em seropositivity and fecundability, live birth, and adverse pregnancy outcomes
衣原体感染前血清阳性与受孕能力、活产和不良妊娠结局
- DOI:
10.1016/j.fertnstert.2024.12.017 - 发表时间:
2025-06-01 - 期刊:
- 影响因子:7.000
- 作者:
Yajnaseni Chakraborti;Stefanie N. Hinkle;Jørgen Skov Jensen;Catherine L. Haggerty;Toni Darville;Sunni L. Mumford;Enrique F. Schisterman;Robert M. Silver;Brandie DePaoli Taylor - 通讯作者:
Brandie DePaoli Taylor
Brandie DePaoli Taylor的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brandie DePaoli Taylor', 18)}}的其他基金
Evaluating the intersection between sexually transmitted infections, inflammation and reproductive success
评估性传播感染、炎症和生殖成功之间的交叉点
- 批准号:
10338181 - 财政年份:2020
- 资助金额:
$ 10.94万 - 项目类别:
Evaluating the intersection between sexually transmitted infections, inflammation and reproductive success
评估性传播感染、炎症和生殖成功之间的交叉点
- 批准号:
10442247 - 财政年份:2020
- 资助金额:
$ 10.94万 - 项目类别:
Evaluating the intersection between sexually transmitted infections, inflammation and reproductive success
评估性传播感染、炎症和生殖成功之间的交叉点
- 批准号:
10576339 - 财政年份:2020
- 资助金额:
$ 10.94万 - 项目类别:
Evaluating the intersection between sexually transmitted infections, inflammation and reproductive success
评估性传播感染、炎症和生殖成功之间的交叉点
- 批准号:
9887442 - 财政年份:2020
- 资助金额:
$ 10.94万 - 项目类别:
Immune activating syncytiotrophoblast microvesicles and danger associated molecular patterns in preeclampsia risk
先兆子痫风险中免疫激活合体滋养层微泡和危险相关分子模式
- 批准号:
10437699 - 财政年份:2019
- 资助金额:
$ 10.94万 - 项目类别:
Immune activating syncytiotrophoblast microvesicles and danger associated molecular patterns in preeclampsia risk
先兆子痫风险中免疫激活合体滋养层微泡和危险相关分子模式
- 批准号:
10655445 - 财政年份:2019
- 资助金额:
$ 10.94万 - 项目类别:
Immune activating syncytiotrophoblast microvesicles and danger associated molecular patterns in preeclampsia risk
先兆子痫风险中免疫激活合体滋养层微泡和危险相关分子模式
- 批准号:
10441912 - 财政年份:2019
- 资助金额:
$ 10.94万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 10.94万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 10.94万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 10.94万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 10.94万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 10.94万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 10.94万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 10.94万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 10.94万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 10.94万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 10.94万 - 项目类别: